Clearmind Medicine Initiates Phase I/IIa Clinical Trial of CMND-100 for Alcohol Use Disorder at Yale School of Medicine
LOS ANGELES– Clearmind Medicine Inc. has selected Yale School of Medicine as the first site in the United States for its Phase I/IIa clinical trial of CMND-100, a proprietary compound aimed at treating alcohol use disorder (AUD). The trial will assess the safety and efficacy of CMND-100, which contains the active ingredient MEAI (5-methoxy-2-aminoindane), a psychoactive compound of the aminoindane class.
During the clinical trial, participants will receive oral capsules of CMND-100 once daily for ten consecutive days. They will then report their drinking patterns and alcohol cravings throughout the trial period. The primary objective of the trial is to determine the tolerable dose and evaluate the safety and pharmacokinetics/pharmacodynamics of single and repeated doses of CMND-100 in both healthy subjects and individuals with AUD. The secondary endpoint will assess the efficacy of CMND-100 in reducing drinking patterns and cravings in individuals with moderate-to-severe AUD.
Anahita Bassir Nia, an expert in substance abuse, including alcohol abuse, will lead the trial at Yale School of Medicine. Clearmind’s CEO, Dr. Adi Zuloff-Shani, expressed confidence in the collaboration, seeing it as validation of CMND-100’s potential as a treatment for AUD.
Clearmind recently received approval from the Ethics Committee of Israel’s IMCA center for the Phase I/IIa clinical trial of CMND-100. The trial, known as CM-CMND-001, is a multinational, multicenter study that will assess the tolerability, safety, and pharmacokinetics of single and multiple doses of CMND-100 in healthy volunteers and individuals with AUD.
With an extensive intellectual property portfolio and a renowned advisory board of psychiatrists and researchers, Clearmind believes CMND-100 has the potential to revolutionize addiction and mental health treatment. The company aims to provide an innovative, self-administered, non-addictive prescription pill that offers immediate therapeutic benefits without the need for expensive therapies.
California’s Legal Cannabis Market Faces Declining Sales in Q1 2023
LOS ANGELES- California's legal cannabis market continues to grapple with challenges, as indicated by the latest tax and sales numbers released by the state's Department of Tax and Fee Administration. According to the agency's report ...
Organigram Enters Partnership with Phylos Bioscience to Enhance Cannabis Genetics and Technical Capabilities
LOS ANGELES-- Organigram Holdings Inc, a licensed producer of cannabis, announced today that it has forged a comprehensive technical and commercial relationship with Phylos Bioscience Inc., a renowned U.S. cannabis genetics company based in Portland, ...
Uncertain Future for Medical Cannabis Expansion in Texas as Legislative Session Nears Conclusion
AUSTIN-- As the Texas legislative session draws to a close this Memorial Day, the future of medical cannabis expansion in the state remains uncertain. Crucial legislation aimed at broadening access to low-THC medical cannabis products ...